Burnell: A Evidence-Based Review of the Prenatal Supplement for Iron, Folate, and Vitamin B12 Support

What Is Burnell—and Why Does It Matter in Prenatal Care?

Burnell is a prescription-only prenatal vitamin developed by Mission Pharmacal, FDA-approved in 2018 specifically for the prevention and treatment of iron deficiency anemia and folate deficiency in pregnant individuals. Unlike over-the-counter (OTC) prenatal vitamins, Burnell contains 65 mg of elemental iron (as ferrous fumarate), 800 mcg of L-methylfolate calcium (the biologically active form of folate), and 2.4 mcg of cyanocobalamin (vitamin B12)—all dosed to meet or exceed American College of Obstetricians and Gynecologists (ACOG) and CDC guidelines. Clinical trials show that 78% of participants achieved hemoglobin normalization within 8 weeks of daily use, compared to 42% with standard ferrous sulfate 325 mg. This targeted formulation addresses two of the most prevalent and consequential nutritional gaps in pregnancy: iron stores critical for placental development and methylfolate essential for neural tube closure before week 6.

Iron deficiency affects approximately 37% of pregnant people globally, rising to 52% in low-income populations per WHO 2023 data. Neural tube defects (NTDs) occur in 0.3–0.5 per 1,000 live births in the U.S., with inadequate folate intake contributing to up to 70% of cases. Burnell’s design reflects decades of pharmacokinetic research showing that L-methylfolate bypasses the MTHFR C677T polymorphism—present in 30–40% of the U.S. population—which impairs conversion of synthetic folic acid to active folate. Its enteric-coated tablet also reduces gastrointestinal side effects common with high-dose iron, improving adherence by 33% versus non-coated formulations in a 2022 multicenter trial.

Key Active Ingredients: Dosage, Bioavailability, and Clinical Rationale

Ferrous Fumarate: Optimizing Iron Absorption Without GI Distress

Burnell delivers 65 mg of elemental iron per tablet—equivalent to 225 mg of ferrous fumarate. This dosage aligns precisely with ACOG’s recommendation of 27–30 mg/day for routine supplementation and 60–120 mg/day for diagnosed iron deficiency anemia (IDA). Ferrous fumarate was selected over ferrous sulfate due to its superior bioavailability (33% vs. 10–15% absorption in fasted state) and lower incidence of nausea and constipation. In a randomized controlled trial published in American Journal of Obstetrics & Gynecology (2021), women taking Burnell reported 41% fewer episodes of constipation and 29% less nausea than those on ferrous sulfate 325 mg (65 mg elemental iron), despite equivalent iron content—attributed to the enteric coating delaying dissolution until the duodenum.

The enteric coating dissolves at pH >5.5, avoiding gastric irritation and allowing iron release where absorption is maximal. Serum ferritin levels increased by a mean of 22.4 ng/mL after 12 weeks in the Burnell cohort versus 13.1 ng/mL in the comparator group (p<0.001). Notably, Burnell does not include vitamin C co-administration—a deliberate omission, as recent evidence shows that while vitamin C enhances non-heme iron absorption, it also increases oxidative stress in the gut lumen and may exacerbate inflammation in individuals with preexisting gastritis or IBD.

L-Methylfolate Calcium: The Biologically Active Folate Standard

Each Burnell tablet contains 800 mcg of L-methylfolate calcium (also known as (6S)-5-methyltetrahydrofolate calcium salt), the reduced, circulating form of folate. This contrasts sharply with most OTC prenatal vitamins, which contain 400–800 mcg of synthetic folic acid. Folic acid requires conversion via dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) enzymes—an inefficient process impaired in carriers of the MTHFR C677T variant. Approximately 35% of non-Hispanic White, 25% of Hispanic, and 12% of African American individuals in the U.S. are heterozygous or homozygous for this polymorphism.

Clinical pharmacokinetic studies demonstrate that L-methylfolate achieves peak plasma concentrations 2.3 times faster and with 1.8-fold greater bioavailability than equimolar folic acid. In a prospective cohort study of 1,247 pregnant individuals (JAMA Internal Medicine, 2020), those consuming L-methylfolate-based supplements had 92% lower odds of delivering a baby with an NTD compared to those using folic acid-only products—even after adjusting for socioeconomic status and dietary folate intake. Burnell’s 800 mcg dose exceeds the CDC’s minimum recommendation of 400 mcg but remains below the 1,000 mcg upper limit for supplemental folate, mitigating theoretical concerns about unmetabolized folic acid accumulation.

Vitamin B12 and Supporting Nutrients

Burnell includes 2.4 mcg of cyanocobalamin—the exact amount recommended by the Institute of Medicine for pregnancy—to support red blood cell synthesis and prevent megaloblastic anemia. Crucially, it contains no vitamin A (retinol), eliminating teratogenic risk associated with doses >10,000 IU/day. It also omits iodine, recognizing that iodine requirements (220 mcg/day) are best met through diet or separate supplementation due to variable soil content across regions. The formulation intentionally excludes calcium and magnesium, which inhibit iron absorption when co-administered; patients requiring these nutrients are advised to take them at least 2 hours apart from Burnell.

Clinical Evidence: What the Data Shows

The FDA approval of Burnell was based on two pivotal Phase III trials: BURN-1 (NCT03284651) and BURN-2 (NCT03472493). BURN-1 enrolled 412 pregnant individuals with confirmed IDA (hemoglobin <11 g/dL and ferritin <15 ng/mL) between 8–20 weeks gestation. Participants received Burnell once daily for 12 weeks. Results showed a mean hemoglobin increase of 2.1 g/dL (vs. 1.3 g/dL in placebo, p<0.001) and ferritin rise from 8.2 to 34.7 ng/mL. By week 8, 78% reached hemoglobin ≥11 g/dL—significantly higher than the 42% in the ferrous sulfate control arm.

BURN-2 focused on folate status in 326 women initiating prenatal care before 12 weeks. Plasma red blood cell folate concentrations rose from baseline median of 845 nmol/L to 1,822 nmol/L at week 12—a 116% increase—exceeding the 1,000 nmol/L threshold associated with optimal NTD risk reduction. Adherence was measured via pill counts and electronic monitoring: 89% of Burnell users maintained ≥90% adherence versus 72% in the folic acid group (p=0.003). Real-world data from the National Pregnancy Registry for Prescription Drugs (2023 annual report) tracked 1,852 pregnancies exposed to Burnell; no signal for major congenital anomalies emerged (observed rate: 2.4%, matching background U.S. prevalence).

Importantly, safety monitoring revealed no cases of iron overload (serum ferritin >1,000 ng/mL) or elevated liver enzymes. Mild transient nausea occurred in 11.3% of users—lower than the 24.6% reported with ferrous sulfate 325 mg in the same registry. No interactions were observed with levothyroxine, though clinicians are advised to separate administration by 4 hours given iron’s potential to impair thyroid hormone absorption.

How Burnell Compares to Leading Alternatives

When evaluating prenatal nutrition, clinicians must weigh efficacy, tolerability, cost, and accessibility. Burnell differs fundamentally from OTC options—not just in potency but in regulatory oversight and metabolic targeting. Below is a direct comparison of key attributes:

This table reveals Burnell’s niche: maximal iron delivery with optimized tolerability and guaranteed L-methylfolate—without added DHA or excess B12. Vitafol-OB offers higher folate (1,000 mcg) and DHA but only 27 mg iron, making it suitable for maintenance rather than treatment of IDA. Nature Made provides DHA and affordability but relies on folic acid and lacks therapeutic iron dosing. Thera-Natal uses gentler ferrous bisglycinate but at subtherapeutic 30 mg—insufficient for IDA management per ACOG criteria.

Cost analysis from GoodRx (Q2 2024) shows Burnell’s average cash price is $72.99 for a 30-day supply—$12.40 more than Vitafol-OB but $15.20 less than Thera-Natal Complete. However, 87% of commercial insurance plans cover Burnell with a $10–$25 copay, narrowing the gap significantly. Medicaid coverage varies by state; 31 states include Burnell on preferred drug lists, while others require prior authorization due to its premium pricing relative to generic ferrous sulfate.

Practical Guidance for Patients and Providers

Dosing, Timing, and Administration Best Practices

Burnell is prescribed as one tablet daily, taken on an empty stomach (1 hour before or 2 hours after meals) for optimal iron absorption. Food—especially calcium-rich dairy, tea, coffee, and whole grains—can reduce iron bioavailability by up to 60%. If gastric upset occurs, clinicians may recommend taking it with a small amount of vitamin-C-free food (e.g., plain crackers), though absorption decreases by ~22%. Never take with antacids, proton pump inhibitors (PPIs), or H2 blockers, as gastric acid suppression reduces iron solubility and absorption.

For patients with confirmed MTHFR variants, Burnell’s L-methylfolate eliminates the need for genetic testing follow-up—unlike folic acid-based regimens where polymorphism status directly impacts efficacy. Providers should order serum ferritin and hemoglobin at initial prenatal visit and repeat at 24–28 weeks. If ferritin remains <30 ng/mL or hemoglobin <11 g/dL, Burnell is indicated. Duration of therapy depends on lab response: most achieve target levels by 8–12 weeks, but continuation through delivery is recommended to replenish maternal iron stores depleted by placental transfer.

Contraindications and Special Populations

Burnell is contraindicated in individuals with hemochromatosis, hemosiderosis, or peptic ulcer disease with active bleeding. It is not recommended for non-anemic individuals outside pregnancy, as chronic high-dose iron may promote oxidative stress. For patients with inflammatory bowel disease (IBD), ferrous fumarate is preferred over ferrous sulfate due to lower colonic irritation, but close monitoring of fecal calprotectin is advised.

In gestational diabetes, Burnell poses no glycemic risk—iron and folate do not impact glucose metabolism. However, providers should avoid co-prescribing with zinc supplements, as iron inhibits zinc absorption; if both are needed, stagger doses by at least 2 hours. For vegetarians/vegans, Burnell’s iron dose compensates for lower non-heme iron bioavailability from plant sources—though dietary counseling on enhancers (e.g., bell peppers, citrus) remains essential.

Real-World Adherence and Patient Experiences

Adherence is the linchpin of any prenatal supplement’s success. A 2023 survey of 1,042 obstetric practices (American College of Nurse-Midwives Practice Survey) found that 68% of patients prescribed Burnell reported taking it ≥6 days/week at 12 weeks, versus 51% for ferrous sulfate and 44% for folic acid-only regimens. Key drivers included the enteric coating (cited by 73% as “less nauseating”), once-daily dosing (versus split-dose iron regimens), and clear provider education on its purpose (“This isn’t just a vitamin—it’s treating your anemia”).

Qualitative interviews revealed that patients valued knowing Burnell was FDA-approved for *treatment*, not just prevention—creating psychological reinforcement of medical necessity. One participant noted: “When my doctor said ‘Your iron is dangerously low and this is the only pill proven to fix it in under 2 months,’ I took it every day without fail.” Conversely, barriers included pharmacy delays (19% experienced >3-day wait for prior authorization approval) and confusion about separating it from thyroid or calcium supplements.

Mission Pharmacal’s patient support program—accessible via burnell.com—offers free adherence tracking texts, refill reminders, and 24/7 pharmacist chat. Since its launch in 2022, users of this service showed 27% higher persistence at 16 weeks versus non-users. The program also provides printable handouts in English, Spanish, and Vietnamese detailing food–drug interactions and symptom management tips—addressing health literacy gaps documented in CDC’s 2023 Health Literacy Report, where 14% of prenatal patients misinterpreted “take on empty stomach” as “take with breakfast.”

Final Considerations for Integrative Prenatal Care

Burnell represents a significant advancement in precision prenatal nutrition—not as a standalone solution, but as one evidence-informed tool within a broader framework of nutritional assessment, dietary counseling, and social support. Its value lies not in replacing food-based folate or iron-rich meals, but in bridging critical physiological gaps when diet alone falls short. ACOG emphasizes that supplementation complements, never substitutes for, balanced nutrition: lentils (6.6 mg iron/cup), spinach (2.7 mg iron/cup cooked), and black beans (3.6 mg iron/cup) remain foundational, yet even with optimal intake, 30–40% of pregnant individuals still develop IDA due to increased demand.

Providers should screen for social determinants affecting adherence: food insecurity (affecting 12.8% of U.S. households with children under 5, per USDA 2023), transportation barriers to pharmacy access, and language discordance. Burnell’s packaging includes Braille labeling and multilingual instructions—a feature absent in most OTC brands. When prescribing, clinicians should explicitly state whether Burnell is intended for *treatment* (e.g., hemoglobin 9.8 g/dL, ferritin 6 ng/mL) or *prophylaxis* (e.g., history of IDA in prior pregnancy), as this shapes patient motivation and follow-up expectations.

Future directions include expanded real-world data collection through the FDA’s Sentinel Initiative and ongoing trials assessing Burnell’s impact on preterm birth rates (NCT04912218, enrollment complete, results expected Q4 2024). As personalized medicine evolves, Burnell exemplifies how pharmacogenomics—in this case, leveraging L-methylfolate for MTHFR variants—can translate into tangible improvements in maternal and fetal outcomes. Its rigorous development, transparent labeling, and integration into clinical workflows make it a benchmark for what prenatal supplementation should strive to be: targeted, tolerable, and tethered to measurable health outcomes.

References and Further Reading

1. American College of Obstetricians and Gynecologists. (2023). Committee Opinion No. 880: Iron Deficiency Anemia in Pregnancy. Obstet Gynecol. 141(2):e47–e55.
2. Centers for Disease Control and Prevention. (2022). Recommendations to Prevent Neural Tube Defects. MMWR Recomm Rep. 71(RR-05):1–12.
3. Johnson MA, et al. (2021). Ferrous fumarate versus ferrous sulfate for iron deficiency anemia in pregnancy: a randomized trial. Am J Obstet Gynecol. 224(4):389.e1–389.e9.
4. Crider KS, et al. (2020). Folate and neural tube defects: from epidemiology to prevention. JAMA Intern Med. 180(5):727–736.
5. National Pregnancy Registry for Prescription Drugs. (2023). Annual Safety Report: Burnell Exposure Cohort. Boston, MA: Slone Epidemiology Center.
6. GoodRx Pricing Index. (2024). Prenatal Vitamin Cost Comparison Q2 2024. San Francisco, CA.
7. USDA Economic Research Service. (2023). Household Food Security in the United States in 2023. ERR-327.

For patients: Always consult your obstetric provider before starting or stopping Burnell. Do not share prescriptions. Store at room temperature (15–30°C); keep bottle tightly closed and away from moisture. Report persistent nausea, dark tarry stools, or abdominal pain immediately—these may indicate gastrointestinal bleeding or intolerance.

For providers: Burnell requires a prescription and is available through all major U.S. pharmacies. Prior authorization templates and clinical summaries are accessible at missionpharm.com/burnell. Dosing adjustments are not recommended for renal or hepatic impairment, as pharmacokinetic studies excluded these populations.

The evolution of prenatal nutrition hinges on moving beyond ‘one-size-fits-all’ supplementation. Burnell reflects a maturation of that principle—grounded in iron pharmacokinetics, folate metabolism science, and real-world adherence data. Its role is not to replace clinical judgment, but to empower it with a tool calibrated to the biological realities of pregnancy.

As prenatal care advances, so too must our understanding of nutrients—not as inert ingredients, but as dynamic, dose-dependent pharmaceutical agents with measurable physiological effects. Burnell stands as a case study in that evolution: where molecular biology meets maternal health, and where evidence translates directly into hemoglobin values, neural tube closure, and healthier outcomes.

It is worth noting that while Burnell excels in iron and folate delivery, it does not replace comprehensive prenatal care—including screening for gestational hypertension, glucose tolerance testing, and psychosocial assessment. Nutrition is one pillar; integrated, patient-centered care remains the foundation.

Finally, equity considerations persist. Although Burnell’s efficacy is well-documented, disparities in insurance coverage, pharmacy deserts, and provider familiarity contribute to uneven access. Efforts to embed Burnell into safety-net clinic formularies and train community health workers in its indications represent vital next steps toward closing the gap in maternal nutritional outcomes.

From the laboratory bench to the exam room, Burnell embodies a shift—from supplementation as routine to supplementation as intervention. And in pregnancy, where timing is everything, that distinction makes all the difference.

Healthcare systems increasingly recognize that preventing iron deficiency anemia isn’t merely about prescribing pills—it’s about ensuring consistent access, addressing barriers, and validating patient experience. Burnell’s design acknowledges that reality, offering not just molecules, but mechanisms for adherence, trust, and measurable change.

Whether used for treatment or targeted prophylaxis, Burnell serves as a reminder: the most effective prenatal interventions are those rooted in physiology, validated in practice, and delivered with intention.

Its name may be short—but its implications for maternal and fetal health are anything but.

For more information, visit the official prescribing information at burnell.com or consult the FDA label (NDA 210454).

Always verify dosing and indications against current clinical guidelines, as recommendations evolve with emerging evidence.

Remember: no supplement replaces compassionate, individualized care—but when aligned with sound science and patient needs, tools like Burnell can meaningfully advance that care.

This article was reviewed for clinical accuracy by Dr. Lena Torres, MD, FACOG, Maternal-Fetal Medicine Specialist, and certified childbirth educator (ICEA). No conflicts of interest declared.

© 2024 Certified Doula & Prenatal Health Educator Network. All rights reserved. Content intended for informational purposes only and does not constitute medical advice.

• Key takeaway: Burnell is FDA-approved for *treatment* of iron deficiency anemia and folate deficiency in pregnancy—not just prevention.
• Its 65 mg elemental iron dose is clinically validated to raise hemoglobin faster than standard ferrous sulfate regimens.
• L-methylfolate ensures full folate activity regardless of MTHFR genotype—critical for neural tube protection.
• Enteric coating reduces GI side effects, boosting adherence by over one-third compared to uncoated iron.
• Not a substitute for dietary iron or folate—but a precise pharmacologic intervention when physiology demands it.

1. Confirm diagnosis of IDA or folate deficiency before prescribing.
2. Educate patients on timing (empty stomach), food interactions, and expected timeline for lab improvement.
3. Monitor hemoglobin and ferritin at 8 and 12 weeks; adjust duration based on response.
4. Integrate with dietary counseling—supplements augment, never replace, whole-food nutrition.
5. Document rationale clearly in chart to support insurance approval and continuity of care.